LWBK1006-Index LWW-Govindan-Review December 19, 2011 19:14
Index 609Hepatocellular carcinoma (HCC),
38, 50, 252
alcohol consumption and, 39, 50
alpha1-antitrypsin deficiency and,
253, 257
characteristics of, 256, 260
and chemoembolization, 543, 548
fibrolamellar, 255, 259
HCV infection and, 38, 39, 50
hemochromatosis and, 253, 257
hepatitis B vaccination and, 253,
257
hepatitis B x gene product and,
256, 260
interferon in, 39, 50
paraneoplastic syndrome and,
253, 257
ribavirin in, 39, 50
surveillance for, 256, 260
Wilson disease and, 253, 257
Hepatosplenic candidiasis, 544, 549
Hepatosplenic T-cell lymphomas,
416, 429
Hereditary cancer syndrome, 36, 47
factors for, 151, 156
Hereditary diffuse gastric cancer
(HDGC), 156–157
Hereditary leiomyomatosis, 47
renal cancer and, 280, 289
Hereditary nonpolyposis colorectal
cancer (HNPCC), 3, 10, 35,
45, 137, 140, 150, 155, 156,
320, 328
causes of, 45
characteristics of, 35, 45, 150,
155–156
gastric adenocarcinoma and, 239
MSH2 and, 269, 275
MSI and, 274
MSI-H phenotype and, 274
Hereditary papillary renal cancer,
280, 289
Her2/neu amplification, in breast
cancer, 4, 11
Herpes simplex virus (HSV), 315
H1F1and VEGF, 21, 29
HHV8.SeeHuman herpes virus 8
(HHV8)
HIDAC.SeeHigh-dose cytarabine
(HIDAC)
Hierarchy model, of tumor
heterogeneity, 23, 32
High-dose cytarabine (HIDAC),
441, 447
High-dose methotrexate, 386, 391
Highly active antiretroviral therapy
(HAART), 497
in KS, 497, 500
High-power field (hpf), 261Hippocampus, effects of radiation
on, 510, 513
Histone deacetylase
inhibition, 19
regulation of, 16
HIV.SeeHuman immunodeficiency
virus (HIV)
HIV infection, and cancer
development, 38, 49
HL.SeeHodgkin’s lymphoma (HL)
HNPCC.SeeHereditary
nonpolyposis colorectal cancer
(HNPCC)
Hodgkin cells or Reed-Sternberg
(HRS), 422
Hodgkin’s disease
immunization before splenectomy
in, 539, 545
and SVC syndrome, 506
Hodgkin’s lymphoma (HL), 52,
394, 404, 499, 501, 519, 523
anti-CD30 antibodies, 427, 435
bispecific anti-CD30 antibodies,
427, 435
breast cancer and, 143, 147
CD20 antigen, 427, 435
CT scanning, 425
HIV-associated, 499, 501
HRS cells in, 422, 433–434
long-term complications in, 425,
435
pregnancy and, 425, 435
staging procedures for, 423,
434
T cells in, 422
treatment-related complications,
425, 435
treatment strategy in, 424, 434
HOG.SeeHoosier Oncology
Group (HOG)
Homologous recombination (HR),
85, 90
Hoosier Oncology Group (HOG),
213
Hormonal therapy, for ovarian
cancer, 307, 312
Horner’s syndrome, 222
Hospital-based palliative care
programs, 568
hpf.SeeHigh-power field (hpf)
HPV.SeeHuman papilloma virus
(HPV)
HR.SeeHazard ratio (HR);
Homologous recombination
(HR)
HRQOL.SeeHealth-related quality
of life (HRQOL)
HRS.SeeHodgkin cells or
Reed-Sternberg (HRS)HSCT.SeeHematopoietic stem cell
transplantation (HSCT)
HSV.SeeHerpes simplex virus
(HSV)
HTLV1.SeeHuman T-cell
lymphotropic virus type I
(HTLV1)
HTLV2, characteristics of, 37, 49
Human cancer, 57, 63
characteristics of, 5, 12
cytogenetic abnormalities in, 5,
12–13
Human chorionic gonadotropin
(hCG), 297, 301, 322, 329,
412
Human Genome Project, 1
Human herpes virus-8 (HHV-8),
40, 52, 499
Castleman’s disease and, 414,
429
characteristics of, 40, 52
Human immunodeficiency virus
(HIV), 37, 297, 301, 497, 500
anal cancer in, 500
anogenital cancers in, 499, 501
associated HL, 499, 501
cervical cancer in, 316
EBV in, 499, 501
hepatitis C virus in, 499, 501
HHV-8 in, 499, 501
HPV infections and, 316
KS and, 40, 52
testicular cancer and, 301
Human papilloma virus (HPV), 39,
51, 141, 195, 199, 315, 323,
499
cervical cancer and, 39, 51, 324
E6 and E7 viral proteins, 39, 51
oropharyngeal cancers and, 39,
51
penile cancers and, 39, 51
prevention and treatment of, 316,
324
smoking and, 39, 51
vaccine, 40, 51–52, 106, 111
vaginal cancer and, 318, 325
Human T-cell lymphotropic virus
type I (HTLV1), 37, 48
Hurthle cell carcinoma, 352, 360
Hydroquinone and benzene oxide,
58, 64
Hyperbaric oxygen, 87, 91–92
Hypercalcemia, 253, 257
treatment of, 505, 507–508
Hypercholesterolemia, 253, 257
Hyperfractionation, 87, 92
Hypertension and anti-VEGF
therapy, 22, 30
Hyperthermia, 87, 92